Megan Tooley, Cardiovascular Roundtable
There is no question the emergence of transcatheter valve technologies—specifically transcatheter aortic valve replacement (TAVR)—has elicited unprecedented excitement from the cardiovascular community in recent years. However, despite this enthusiasm, the reality is only a portion of hospitals will meet the strict resource and volume requirements necessary to become TAVR sites in the near future.
This may leave many of you wondering, “So what if we’re not a TAVR program? Is there still a place for us in the valve market?” You’re not alone, and as we explore in our national meeting series, your options for treating valve disease and disorders do not end at TAVR.
Learn how one Roundtable member is ensuring their patients have access to a full range of valve services—even if they’re not the TAVR program.
So you're not a TAVR program—Now what?
Nicole MacMillan, Cardiovascular Roundtable
With the recent release of the Society for Cardiovascular Angiography and Interventions’ (SCAI) consensus statement on ad hoc PCI, the discussion around informed consent for cardiac procedures has again risen to the forefront of our members’ topics of interest.
One study we discussed previously suggests that patient education surrounding elective PCI decisions is often infrequent and ripe for improvement. This dialogue with patients will become increasingly critical as providers seek to activate patients in their care to secure both loyalty and engagement throughout the treatment process.
Informed consent for cardiovascular procedures: Resources for your program
Final results of the five-year SYNTAX trial find CABG surgery delivers better outcomes than PCI for intermediate-high risk patients.
This trend was surprisingly apparent for patients with three-vessel disease and at high risk for surgical complication. However, patients who underwent CABG or PCI that had left main disease with fewer than three vessels affected had equivalent rates of major adverse cardiac and cerebrovascular events (MACCE).
Nevertheless, researchers note that nearly 80% of patients with three-vessel disease have a 79% improved survival rate with surgery over PCI. These results suggest that for high-risk patients, surgery may be the best treatment pathway, demonstrating fewer downstream complications.
SYNTAX trial confirms surgery best for most patients